Table 1.
Clinical characteristics of 399 patients according to cN status prior to neoadjuvant treatment.
| cN0 | cN1/2 | |
|---|---|---|
| All | 219 (54.8%) | 180 (45.2%) |
| Age (years) | ||
| <35 | 21 (9.6%) | 12 (6.7%) |
| 35–49 | 105 (47.9%) | 89 (49.4%) |
| 50–69 | 80 (36.5%) | 70 (38.9%) |
| >70 | 13 (5.9%) | 9 (5%) |
| Breast Related Cancer Antigens (BRCA) mutations | 29 (13.2%) | 16 (47.2%) |
| Menopausal status | 103 (47%) | 85 (47.2%) |
| Grading | ||
| G1 | 3 (1.4%) | 2 (1.1%) |
| G2 | 78 (35.6%) | 66 (36.7%) |
| G3 | 118 (53.9%) | 96 (53.3%) |
| Unknown | 20 (9.1%) | 16 (8.9%) |
| Tumor subtype | ||
| Luminal A | 8 (3.7%) | 3 (1.7%) |
| Luminal B | 152 (69.4%) | 133 (73.9%) |
| HER 2 positive | 17 (7.8%) | 16 (8.9%) |
| Triple negative | 42 (19.2%) | 28 (15.6%) |
| Clinical T | ||
| cT1 | 28 (12.8%) | 27 (15%) |
| cT2 | 146 (66.7%) | 105 (58.3%) |
| cT3 | 29 (13.2%) | 33 (18.3%) |
| cT4 | 16 (7.3%) | 15 (8.3%) |
| Multifocality/multicentricity | 91 (41.6%) | 92 (51.1%) |